NASDAQ:SRRK Scholar Rock (SRRK) Stock Price, News & Analysis $9.28 -0.17 (-1.80%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.22▼$9.8650-Day Range$7.63▼$12.5252-Week Range$5.93▼$21.17Volume640,316 shsAverage Volume839,761 shsMarket Capitalization$740.08 millionP/E RatioN/ADividend YieldN/APrice Target$26.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Scholar Rock alerts: Email Address Scholar Rock MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside180.2% Upside$26.00 Price TargetShort InterestBearish17.33% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.90Based on 4 Articles This WeekInsider TradingSelling Shares$147,883 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.40) to ($2.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.31 out of 5 starsMedical Sector149th out of 936 stocksBiological Products, Except Diagnostic Industry15th out of 154 stocks 3.6 Analyst's Opinion Consensus RatingScholar Rock has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageScholar Rock has only been the subject of 3 research reports in the past 90 days.Read more about Scholar Rock's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.33% of the outstanding shares of Scholar Rock have been sold short.Short Interest Ratio / Days to CoverScholar Rock has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Scholar Rock has recently increased by 3.44%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldScholar Rock does not currently pay a dividend.Dividend GrowthScholar Rock does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreScholar Rock has received a 71.31% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Scholar Rock is -0.81. Previous Next 3.3 News and Social Media Coverage News SentimentScholar Rock has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Scholar Rock this week, compared to 3 articles on an average week.Search Interest2 people have searched for SRRK on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scholar Rock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $147,883.00 in company stock.Percentage Held by Insiders26.20% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scholar Rock's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Scholar Rock are expected to grow in the coming year, from ($2.40) to ($2.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scholar Rock is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scholar Rock is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScholar Rock has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Scholar Rock's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Scholar Rock Stock (NASDAQ:SRRK)Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Read More SRRK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRRK Stock News HeadlinesJuly 22, 2024 | msn.comMusic Industry Moves: Metallica Expands Scholars Initiative Program Nationwide, Announces Benefit Concert and AuctionJuly 20, 2024 | lse.co.ukScholar Rock Holding Corp Share ChatJuly 27, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 24, 2024 | businesswire.comScholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist WithdrawalJune 18, 2024 | businesswire.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2024 | businesswire.comScholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual MeetingMay 28, 2024 | businesswire.comScholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Scholar Rock Holding on Strong Drug Pipeline and Market ReadinessJuly 27, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 22, 2024 | businesswire.comScholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in ObesityMay 20, 2024 | businesswire.comScholar Rock to Participate in Upcoming Investor ConferencesMay 17, 2024 | businesswire.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 14, 2024 | businesswire.comScholar Rock to Host Investor Day on May 22, 2024May 8, 2024 | markets.businessinsider.comBuy Rating Justified by Scholar Rock’s Promising Pipeline and Strategic Clinical AdvancementsMay 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Zimmer Biomet Holdings (ZBH)May 7, 2024 | finance.yahoo.comScholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed AnalysisMay 7, 2024 | investorplace.comSRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024May 7, 2024 | businesswire.comScholar Rock Reports First Quarter 2024 Financial Results and Highlights Business ProgressSee More Headlines Receive SRRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRRK CUSIPN/A CIK1727196 Webwww.scholarrock.com Phone(857) 259-3860Fax866-493-4935Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$26.00 High Stock Price Target$31.00 Low Stock Price Target$20.00 Potential Upside/Downside+180.2%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-94.20% Return on Assets-65.81% Debt Debt-to-Equity Ratio0.24 Current Ratio6.58 Quick Ratio6.58 Sales & Book Value Annual Sales$33.19 million Price / Sales22.30 Cash FlowN/A Price / Cash FlowN/A Book Value$3.12 per share Price / Book2.97Miscellaneous Outstanding Shares79,750,000Free Float58,858,000Market Cap$740.08 million OptionableOptionable Beta0.85 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Jay Thomas Backstrom M.D. (Age 69)M.P.H., President, CEO & Director Comp: $1.07MMr. Edward H. Myles MBA (Age 52)CFO, COO & Treasurer Comp: $720.79kMs. Tracey M. Sacco M.B.A. (Age 48)Chief Commercial Officer Comp: $548.86kMr. Mo Qatanani Ph.D. (Age 51)Chief Scientific Officer Rushmie NofsingerVice President of Corporate Affairs & Investor RelationsMs. Junlin Ho J.D. (Age 45)General Counsel & Corporate Secretary Comp: $563.73kMs. Caryn Parlavecchio (Age 52)Chief Human Resources Officer Ms. Lisa Amaya PriceSenior Vice President of Human ResourcesMs. Erin Moore (Age 49)Senior Vice President of Finance Mr. Ryan IarrobinoSenior Vice President of Clinical Development & OperationsMore ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXC4 TherapeuticsNASDAQ:CCCCCoherus BioSciencesNASDAQ:CHRSMoonLake ImmunotherapeuticsNASDAQ:MLTXMorphicNASDAQ:MORFView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 33,468 shares on 7/26/2024Ownership: 0.289%Values First Advisors Inc.Bought 25,979 shares on 7/19/2024Ownership: 0.033%DNB Asset Management ASBought 4,390 shares on 7/5/2024Ownership: 0.025%Junlin HoSold 4,695 sharesTotal: $42,161.10 ($8.98/share)Edward H MylesSold 9,458 sharesTotal: $84,932.84 ($8.98/share)View All Insider TransactionsView All Institutional Transactions SRRK Stock Analysis - Frequently Asked Questions How have SRRK shares performed this year? Scholar Rock's stock was trading at $18.80 at the beginning of 2024. Since then, SRRK shares have decreased by 50.6% and is now trading at $9.28. View the best growth stocks for 2024 here. How were Scholar Rock's earnings last quarter? Scholar Rock Holding Co. (NASDAQ:SRRK) announced its earnings results on Tuesday, May, 7th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.11. When did Scholar Rock IPO? Scholar Rock (SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Scholar Rock's major shareholders? Top institutional shareholders of Scholar Rock include Bank of New York Mellon Corp (0.29%), Values First Advisors Inc. (0.03%) and DNB Asset Management AS (0.02%). Insiders that own company stock include Public Equities LP Invus, Samsara Biocapital Gp, Llc, Amir Nashat, Jay T Backstrom, Junlin Ho, Edward H Myles, Mo Qatanani, Caryn Parlavecchio and Jeffrey S Flier. View institutional ownership trends. How do I buy shares of Scholar Rock? Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Scholar Rock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR) and SCYNEXIS (SCYX). This page (NASDAQ:SRRK) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scholar Rock Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scholar Rock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
